Maxwell Skor, an analyst from Morgan Stanley, has initiated a new Buy rating on Ultragenyx Pharmaceutical (RARE).
Maxwell Skor has given his Buy rating due to a combination of factors that highlight Ultragenyx Pharmaceutical’s potential for growth and profitability. The company has shown strong performance with its flagship product, Crysvita, particularly in the Latin American market, which represents a significant growth opportunity. Additionally, the company’s pipeline is advancing, with setrusumab’s Phase 3 data for Osteogenesis Imperfecta being a key catalyst expected to drive further growth.
Ultragenyx’s revenue guidance for 2025 remains robust, with expectations of reaching $640-670 million, supported by the continued demand for Crysvita and Dojolvi. The management’s target for achieving GAAP profitability by 2027, driven by double-digit growth and potential new product launches, further strengthens the investment case. The progress in their pipeline, including the anticipated BLA filing for DTX401 and the potential launch of UX111, adds to the company’s promising outlook.
In another report released on February 25, Cantor Fitzgerald also maintained a Buy rating on the stock with a $118.00 price target.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RARE in relation to earlier this year.